Spots Global Cancer Trial Database for Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer Patients
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer Patients
Official Title: Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of PCI-24781 Administered Orally in Patients With Advanced Cancer
Study ID: NCT00562224
Interventions
Study Description
Brief Summary: To determine the highest dose of study drug that can be taken without causing serious side effects in patients with advanced cancer. The study will look at safety of the study drug and whether the treatment schedule is tolerated by patients.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
California Cancer Care, Greenbrae, California, United States
University of Chicago, Chicago, Illinois, United States
Sarah Cannon Research Institue, Nashville, Tennessee, United States
MD Anderson Cancer Center, Houston, Texas, United States
Contact Details
Name: Samir Undevia, MD
Affiliation: University of Chicago
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
